Objective To investigated the influence factors of local recurrence after breast conserving therapy (BCT) in young patients with breast cancer.Methods A total of 360 cases of BCT in this hospital from January 2005 to January 2010 were collected and retrospectively analyzed.Clinical and pathological data included the tumor size,lymph node status,tumor TNM stage,pathological type,margin status,human epidermal growth factor receptor 2 (Her-2),estrogen receptor (ER)/progesterone receptor (PR) and Ki-67.The independent risk factors were analyzed by adopting the univariate analysis and Logistic regression analysis.Results The total recurrence rate of young patients with BCT was 10.56％.The univariate analysis showed that the tumor size,TNM stage,pathological type and ER/PR ratio had no influence on local recurrence after BCT in young patients (P＞0.05);lymph node metastasis,cutting edge status,Her-2 and Ki-67 could influence the local recurrence rate after BCT in young patients (P＜0.05).The Logistic regression analysis showed that the lymph node status,Her-2 and margin status were the independent risk factors for local recurrence after BCT in young patients (P＜0.05).Conclusion Lymph node metastases,Her-2 positive and cutting edge status are local recurrence risk factor after BCT for young patients with breast cancer

[摘 要] PD-1/PD-L1抑制剂在乳腺癌免疫治疗中的应用已逐渐成为一种重要的治疗手段，然而对乳腺癌，尤其是三阴性乳腺癌（TNBC）的免疫治疗仍存在某些亟待解决的科学问题，包括PD-1/PD-L1抑制剂单药治疗的有效率欠佳，目前尚无明确的生物标志物来有效筛查治疗敏感人群，免疫相关不良反应（irAE）的发生率高。为了提高疗效和减少irAE的发生，采取以下措施是非常重要的：探讨PD-1/PD-L1抑制剂与其他药物的联合应用方案；采用纳米技术开发选择性靶向肿瘤细胞的纳米载体，降低抗肿瘤药物毒性并提高疗效；探寻开发可预测免疫治疗反应潜力的生物标志物；早期识别和诊疗irAE并建设多学科诊疗协作组（MDT）模式。随着这些措施的积极推进和问题的不断解决，PD-1/PD-L1抑制剂在乳腺癌的治疗中必将呈现出更为广阔的应用前景。